These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31642904)

  • 81. Clinical Implication of Phosphodiesterase-4-Inhibition.
    Schick MA; Schlegel N
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163131
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
    Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
    Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Phosphodiesterase Type 4 Inhibition in CNS Diseases.
    Blokland A; Heckman P; Vanmierlo T; Schreiber R; Paes D; Prickaerts J
    Trends Pharmacol Sci; 2019 Dec; 40(12):971-985. PubMed ID: 31704172
    [TBL] [Abstract][Full Text] [Related]  

  • 84. PDE4D: A Multipurpose Pharmacological Target.
    Lusardi M; Rapetti F; Spallarossa A; Brullo C
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125619
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Systematic Analysis of Biological Processes Reveals Gene Co-expression Modules Driving Pathway Dysregulation in Alzheimer's Disease.
    Adeoye T; Shah SI; Ullah G
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559218
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease.
    Armstrong P; Güngör H; Anongjanya P; Tweedy C; Parkin E; Johnston J; Carr IM; Dawson N; Clapcote SJ
    Neuropsychopharmacology; 2024 Sep; 49(10):1559-1568. PubMed ID: 38521860
    [TBL] [Abstract][Full Text] [Related]  

  • 87. cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression.
    Gulliver C; Busiau T; Byrne A; Findlay JE; Hoffmann R; Baillie GS
    Mol Oncol; 2024 Mar; 18(3):707-725. PubMed ID: 38126155
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Anti-Neurodegenerating Activity: Structure-Activity Relationship Analysis of Flavonoids.
    Preet G; Haj Hasan A; Ramlagan P; Fawdar S; Boulle F; Jaspars M
    Molecules; 2023 Oct; 28(20):. PubMed ID: 37894669
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
    Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
    Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Phosphodiesterase inhibitors in psychiatric disorders.
    Sadeghi MA; Nassireslami E; Yousefi Zoshk M; Hosseini Y; Abbasian K; Chamanara M
    Psychopharmacology (Berl); 2023 Jun; 240(6):1201-1219. PubMed ID: 37060470
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.
    Bondarev AD; Attwood MM; Jonsson J; Chubarev VN; Tarasov VV; Liu W; Schiöth HB
    Front Pharmacol; 2022; 13():1057083. PubMed ID: 36506513
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease.
    Sheng J; Zhang S; Wu L; Kumar G; Liao Y; Gk P; Fan H
    Front Aging Neurosci; 2022; 14():1019187. PubMed ID: 36268188
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches.
    Lugnier C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142518
    [TBL] [Abstract][Full Text] [Related]  

  • 94. CircAXL Knockdown Alleviates Aβ
    Meng S; Wang B; Li W
    Neurochem Res; 2022 Jun; 47(6):1707-1720. PubMed ID: 35229272
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Baicalein Ameliorates Aβ-Induced Memory Deficits and Neuronal Atrophy
    Shi J; Li Y; Zhang Y; Chen J; Gao J; Zhang T; Shang X; Zhang X
    Front Pharmacol; 2021; 12():794458. PubMed ID: 34966284
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease.
    Qin W; Zhou A; Zuo X; Jia L; Li F; Wang Q; Li Y; Wei Y; Jin H; Cruchaga C; Benitez BA; Jia J
    Hum Mol Genet; 2021 May; 30(9):811-822. PubMed ID: 33835157
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Age-related calcium dysregulation linked with tau pathology and impaired cognition in non-human primates.
    Datta D; Leslie SN; Wang M; Morozov YM; Yang S; Mentone S; Zeiss C; Duque A; Rakic P; Horvath TL; van Dyck CH; Nairn AC; Arnsten AFT
    Alzheimers Dement; 2021 Jun; 17(6):920-932. PubMed ID: 33829643
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Compartmentalized Signaling in Aging and Neurodegeneration.
    Di Benedetto G; Iannucci LF; Surdo NC; Zanin S; Conca F; Grisan F; Gerbino A; Lefkimmiatis K
    Cells; 2021 Feb; 10(2):. PubMed ID: 33671541
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Phosphodiesterase PDE4D Is Decreased in Frontal Cortex of Aged Rats and Positively Correlated With Working Memory Performance and Inversely Correlated With PKA Phosphorylation of Tau.
    Leslie SN; Datta D; Christensen KR; van Dyck CH; Arnsten AFT; Nairn AC
    Front Aging Neurosci; 2020; 12():576723. PubMed ID: 33192469
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.